Skip to main content

Table 5 Stage II variables used for multivariable analyses

From: Biomarkers for the detection of renal fibrosis and prediction of renal outcomes: a systematic review

Reference Biomarker Patient Population Variables used for multivariable analyses
Chen et al [29] Urine TGF- β Unilateral ureteral obstruction requiring percutaneous nephrostomy NA
Harris et al [30] Blood TGF- β Renal transplant recipients Acute cellular rejection
Wong et al [31] Blood total and active TGF- β 1 Type II diabetes Sex, age, baseline eGFR, randomized treatment interventionsa, urinary albumin/creatinine ratio, hemoglobin A1c, BMI, diabetes duration, and history of macrovascular or microvascular disease
Hsu et al [27] Blood MMP-2 Non diabetic patients referred for coronary angiography Age, sex, smoking status, BMI, systolic blood pressure, fasting glucose, total cholesterol, and baseline eGFR
Shi et al [28] Urine MMP-2 Chronic tubulointerstitial nephropathy Age, baseline eGFR, mean blood pressure
Titan et al [32] Urine MCP-1 Macroalbuminuric type II diabetes Baseline creatinine clearance, baseline 24 h proteinuria, and systolic blood pressure
Verhave et al [33] Urine MCP-1 Diabetic nephropathy Proteinuria, TGF-B
Ogliari et al [34] Blood MCP-1 SPK recipients Hemoglobin A1c, years of dialysis pre transplant, recipient BMI, enteric drainage, >1 episode of rejection, type of immunosuppression
Nadkarni et al [35] Urine MCP-1 Type II diabetes Hemoglobin A1c, mean arterial pressure, history of cardiovascular disease, intensive glycemic and blood pressure control, fibrates, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, thiazolidinedione, baseline eGFR, urinary albumin-creatinine ratio.
  1. BMI Basic metabolic panel, eGFR estimated glomerular filtration rate, HC Healthy controls, HR Hazard ratio, MMP-2 matrix metalloprotinease-2, MCP-1 monocyte chemoattractant protein-1, NA not applicable, SPK simultaneous pancreas kidney transplant, TGF-β Transforming growth factor-beta
  2. aWong et al was an ancillary study from the ADVANCE trial cohort, which randomized participants to intensive glucose control, targeting a hemoglobin A1c of ≤6.5%, or to standard, guideline-based glucose control, as well as to combination perindopril–indapamide therapy or to matching placebo